The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.
News|Articles|June 10, 2026
FDA Action Update, May 2026: Approvals, Priority Review, and Extension of Review
Author(s)Isabella Ciccone, MPH
Catch up on any of the neurology headlines you may have missed in May 2026, compiled into 1 place by the NeurologyLive® team.
Advertisement
Advertisement
The FDA was busy in May 2026, making a number of decisions on potential new therapeutic agents, including accepting a resubmission, granting a clearance, and issuing a complete response letter.
Related to this article
Catch up on any of the neurology headlines you may have missed in October 2026, compiled into 1 place by the NeurologyLive® team.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 13, 2026.
Here's some of what is coming soon to NeurologyLive® this week.
The FDA granted fast track designation to FRP-003, an investigational oral botanical drug candidate for Long COVID, ahead of a planned phase 2 trial evaluating fatigue in approximately 220 adults.
GV101 receives FDA fast track designation for the treatment of Friedreich ataxia, with a phase 2 trial planned to begin enrollment in late 2026.
The FDA has approved asundexian, the first factor XIa inhibitor indicated to reduce recurrent stroke after a noncardioembolic ischemic stroke or high-risk TIA, based on phase 3 OCEANIC-STROKE data.
Postmarketing reports of product-related insertional oncogenesis involving GLI1 have prompted an FDA investigation into malignancy risk with SMA gene therapy, onasemnogene abeparvovec.
Advertisement
Advertisement